290 related articles for article (PubMed ID: 33638902)
1. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
2. Impaired Hepatic Very Low-Density Lipoprotein Secretion Promotes Tumorigenesis and Is Accelerated with Fabp1 Deletion.
Newberry EP; Molitor EA; Liu A; Chong K; Liu X; Alonso C; Mato JM; Davidson NO
Am J Pathol; 2024 Jun; 194(6):958-974. PubMed ID: 38417694
[TBL] [Abstract][Full Text] [Related]
3. Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.
Newberry EP; Xie Y; Kennedy SM; Graham MJ; Crooke RM; Jiang H; Chen A; Ory DS; Davidson NO
Hepatology; 2017 Mar; 65(3):836-852. PubMed ID: 27862118
[TBL] [Abstract][Full Text] [Related]
4. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
8. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
9. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
10. Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression.
Cheng D; Xu X; Simon T; Boudyguina E; Deng Z; VerHague M; Lee AH; Shelness GS; Weinberg RB; Parks JS
J Biol Chem; 2016 Nov; 291(45):23793-23803. PubMed ID: 27655915
[TBL] [Abstract][Full Text] [Related]
11. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
12. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
[No Abstract] [Full Text] [Related]
13. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
14. Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.
Alves-Bezerra M; Li Y; Acuña M; Ivanova AA; Corey KE; Ortlund EA; Cohen DE
Hepatology; 2019 Aug; 70(2):496-510. PubMed ID: 30516845
[TBL] [Abstract][Full Text] [Related]
15. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
[TBL] [Abstract][Full Text] [Related]
16. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.
Blanc V; Riordan JD; Soleymanjahi S; Nadeau JH; Nalbantoglu I; Xie Y; Molitor EA; Madison BB; Brunt EM; Mills JC; Rubin DC; Ng IO; Ha Y; Roberts LR; Davidson NO
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33445170
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet.
Imai N; Suzuki M; Hayashi K; Ishigami M; Hirooka Y; Abe T; Shioi G; Goto H; Fujimoto T
PLoS One; 2015; 10(5):e0127114. PubMed ID: 25970332
[TBL] [Abstract][Full Text] [Related]
18. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
19. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
[TBL] [Abstract][Full Text] [Related]
20. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Kozlitina J; Smagris E; Stender S; Nordestgaard BG; Zhou HH; Tybjærg-Hansen A; Vogt TF; Hobbs HH; Cohen JC
Nat Genet; 2014 Apr; 46(4):352-6. PubMed ID: 24531328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
